Neuronetics, Inc. Logo

Neuronetics, Inc.

STIM

(1.0)
Stock Price

1,39 USD

-33.54% ROA

-160.79% ROE

-0.8x PER

Market Cap.

26.058.946,00 USD

312.67% DER

0% Yield

-50.09% NPM

Neuronetics, Inc. Stock Analysis

Neuronetics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Neuronetics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.85x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock maintains a fair debt to equity ratio (88%), indicating a reasonable balance between the money it owes and the ownership it possesses.

3 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

4 ROE

The stock's ROE indicates a negative return (-61.06%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-32.52%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-3), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Neuronetics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Neuronetics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Neuronetics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Neuronetics, Inc. Revenue
Year Revenue Growth
2016 34.228.000
2017 40.433.000 15.35%
2018 52.776.000 23.39%
2019 62.656.000 15.77%
2020 49.244.000 -27.24%
2021 55.312.000 10.97%
2022 65.206.000 15.17%
2023 71.536.000 8.85%
2023 71.348.000 -0.26%
2024 65.800.000 -8.43%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Neuronetics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2016 8.223.000
2017 7.937.000 -3.6%
2018 8.232.000 3.58%
2019 13.747.000 40.12%
2020 9.201.000 -49.41%
2021 7.923.000 -16.13%
2022 9.336.000 15.13%
2023 8.620.000 -8.31%
2023 9.515.000 9.41%
2024 8.940.000 -6.43%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Neuronetics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 6.926.000
2017 8.572.000 19.2%
2018 13.667.000 37.28%
2019 17.457.000 21.71%
2020 18.236.000 4.27%
2021 25.554.000 28.64%
2022 25.516.000 -0.15%
2023 25.356.000 -0.63%
2023 25.426.000 0.28%
2024 24.592.000 -3.39%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Neuronetics, Inc. EBITDA
Year EBITDA Growth
2016 -8.726.000
2017 -12.655.000 31.05%
2018 -19.527.000 35.19%
2019 -24.294.000 19.62%
2020 -21.066.000 -15.32%
2021 -26.114.000 19.33%
2022 -31.260.000 16.46%
2023 -30.832.000 -1.39%
2023 -28.548.000 -8%
2024 -31.808.000 10.25%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Neuronetics, Inc. Gross Profit
Year Gross Profit Growth
2016 27.606.000
2017 30.801.000 10.37%
2018 40.329.000 23.63%
2019 47.267.000 14.68%
2020 37.690.000 -25.41%
2021 43.659.000 13.67%
2022 49.723.000 12.2%
2023 47.056.000 -5.67%
2023 49.699.000 5.32%
2024 46.496.000 -6.89%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Neuronetics, Inc. Net Profit
Year Net Profit Growth
2016 -11.234.000
2017 -16.059.000 30.05%
2018 -24.097.000 33.36%
2019 -34.300.000 29.75%
2020 -32.277.000 -6.27%
2021 -35.602.000 9.34%
2022 -39.207.000 9.19%
2023 -37.564.000 -4.37%
2023 -30.189.000 -24.43%
2024 -39.328.000 23.24%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Neuronetics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 -1.001
2017 -1.431 30.05%
2018 -3 -71450%
2019 -2 -100%
2020 -2 0%
2021 -1 0%
2022 -1 0%
2023 -1 0%
2023 -1 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Neuronetics, Inc. Free Cashflow
Year Free Cashflow Growth
2016 -8.865.000
2017 -11.738.000 24.48%
2018 -21.602.000 45.66%
2019 -31.295.000 30.97%
2020 -29.120.000 -7.47%
2021 -30.336.000 4.01%
2022 -34.008.000 10.8%
2023 -34.406.999 1.16%
2023 -10.676.000 -222.28%
2024 -5.585.000 -91.15%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Neuronetics, Inc. Operating Cashflow
Year Operating Cashflow Growth
2016 -8.541.000
2017 -11.144.000 23.36%
2018 -20.591.000 45.88%
2019 -30.482.000 32.45%
2020 -28.390.000 -7.37%
2021 -27.983.000 -1.45%
2022 -30.739.000 8.97%
2023 -32.037.999 4.05%
2023 -10.124.000 -216.46%
2024 -4.969.000 -103.74%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Neuronetics, Inc. Capital Expenditure
Year Capital Expenditure Growth
2016 324.000
2017 594.000 45.45%
2018 1.011.000 41.25%
2019 813.000 -24.35%
2020 730.000 -11.37%
2021 2.353.000 68.98%
2022 3.269.000 28.02%
2023 2.369.000 -37.99%
2023 552.000 -329.17%
2024 616.000 10.39%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Neuronetics, Inc. Equity
Year Equity Growth
2016 -177.124.000
2017 -192.652.000 8.06%
2018 71.042.000 371.18%
2019 47.852.000 -48.46%
2020 25.493.000 -87.71%
2021 85.175.000 70.07%
2022 57.060.000 -49.27%
2023 37.941.000 -50.39%
2023 34.190.000 -10.97%
2024 19.386.000 -76.36%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Neuronetics, Inc. Assets
Year Assets Growth
2016 24.798.000
2017 38.938.000 36.31%
2018 117.022.000 66.73%
2019 100.168.000 -16.83%
2020 78.657.000 -27.35%
2021 141.223.000 44.3%
2022 116.884.000 -20.82%
2023 92.988.000 -25.7%
2023 115.831.000 19.72%
2024 96.813.000 -19.64%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Neuronetics, Inc. Liabilities
Year Liabilities Growth
2016 201.922.000
2017 231.590.000 12.81%
2018 45.980.000 -403.68%
2019 52.316.000 12.11%
2020 53.164.000 1.6%
2021 56.048.000 5.15%
2022 59.824.000 6.31%
2023 55.047.000 -8.68%
2023 81.641.000 32.57%
2024 77.427.000 -5.44%

Neuronetics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.4
Net Income per Share
-1.08
Price to Earning Ratio
-0.8x
Price To Sales Ratio
0.36x
POCF Ratio
-1.03
PFCF Ratio
-0.95
Price to Book Ratio
1.33
EV to Sales
0.64
EV Over EBITDA
-1.78
EV to Operating CashFlow
-1.84
EV to FreeCashFlow
-1.68
Earnings Yield
-1.26
FreeCashFlow Yield
-1.05
Market Cap
0,03 Bil.
Enterprise Value
0,05 Bil.
Graham Number
3.96
Graham NetNet
-0.55

Income Statement Metrics

Net Income per Share
-1.08
Income Quality
0.77
ROE
-1.09
Return On Assets
-0.49
Return On Capital Employed
-0.48
Net Income per EBT
1
EBT Per Ebit
1.32
Ebit per Revenue
-0.38
Effective Tax Rate
0.18

Margins

Sales, General, & Administrative to Revenue
0.34
Research & Developement to Revenue
0.12
Stock Based Compensation to Revenue
0.09
Gross Profit Margin
0.74
Operating Profit Margin
-0.38
Pretax Profit Margin
-0.5
Net Profit Margin
-0.5

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.83
Free CashFlow per Share
-0.91
Capex to Operating CashFlow
-0.1
Capex to Revenue
0.03
Capex to Depreciation
1.14
Return on Invested Capital
-0.3
Return on Tangible Assets
-0.34
Days Sales Outstanding
98.8
Days Payables Outstanding
71.7
Days of Inventory on Hand
107.36
Receivables Turnover
3.69
Payables Turnover
5.09
Inventory Turnover
3.4
Capex per Share
0.08

Balance Sheet

Cash per Share
1,44
Book Value per Share
0,65
Tangible Book Value per Share
0.65
Shareholders Equity per Share
0.65
Interest Debt per Share
2.24
Debt to Equity
3.13
Debt to Assets
0.63
Net Debt to EBITDA
-0.77
Current Ratio
2.58
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
50456000
Working Capital
0,05 Bil.
Intangibles to Total Assets
0
Average Receivables
0,02 Bil.
Average Payables
0,00 Bil.
Average Inventory
6418000
Debt to Market Cap
2.33

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Neuronetics, Inc. Dividends
Year Dividends Growth

Neuronetics, Inc. Profile

About Neuronetics, Inc.

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

CEO
Mr. Keith J. Sullivan
Employee
203
Address
3222 Phoenixville Pike
Malvern, 19355

Neuronetics, Inc. Executives & BODs

Neuronetics, Inc. Executives & BODs
# Name Age
1 Mr. Rusty Page
Senior Vice President of Operations & Quality
70
2 Mr. Cory S. Anderson
Senior Vice President of R&D and Clinical
70
3 Mr. Stephen J. Furlong M.S.
Executive Vice President, Chief Financial Officer & Treasurer
70
4 Ms. Lisa Metzner-Rosas
Senior Vice President & Chief Marketing Officer
70
5 Ms. Sara Grubbs
Senior Vice President & Chief Revenue Officer
70
6 Mr. Keith J. Sullivan
President, Chief Executive Officer & Director
70
7 Mr. Rick Grubbs
Senior Vice President of National Accounts
70

Neuronetics, Inc. Competitors